Tokyo, Japan

Hideyo Kumazawa

This inventor holds 1 USPTO granted patent. Top assignee: Merck + Co., Inc.. Active years: 2003.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hideyo Kumazawa. Retrieved from https://idiyas.com/inventor/hideyo-kumazawa-mviptons

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2003

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Hideyo Kumazawa

Introduction

Hideyo Kumazawa is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of chemistry, particularly in the preparation of optically active compounds. His work has implications in various industries, including pharmaceuticals.

Latest Patents

Kumazawa holds a patent for a "Process for preparing optically active 1,2-diols." This innovation showcases his expertise in developing methods that enhance the production of important chemical compounds.

Career Highlights

Kumazawa is currently employed at Merck & Co., Inc., a leading global healthcare company. His role at Merck allows him to work on cutting-edge research and development projects that aim to improve health outcomes worldwide.

Collaborations

He has collaborated with esteemed colleagues such as Tamotsu Eguchi and Kenichi Mochida. These partnerships have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Hideyo Kumazawa's contributions to the field of chemistry and his innovative patent reflect his dedication to advancing scientific knowledge. His work continues to influence the industry and inspire future inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…